From the Department of Anesthesiology and Pain Medicine (N.K.J., D.N.W., K.S.L., H.W.) Interdepartmental Division of Critical Care Medicine (H.W.), University of Toronto, Toronto, Canada the Institute of Health Policy Management and Evaluation, Toronto, Canada (N.K.J., D.N.W., K.S.L., H.W.) the University of Limerick, Limerick, Ireland (F.R.) the Sunnybrook Research Institute, Toronto, Canada (J.B., H.W.) the Department of Anesthesia and Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Canada (D.N.W., K.S.L.) the Department of Anesthesia, Perioperative, and Pain Medicine, and Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (B.T.B.) the Department of Anesthesiology and Critical Care, Perelman School of Medicine and Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, Pennsylvania (M.D.N.) the Department of Critical Care Medicine, Sunnybrook Health Sciences Centre, Toronto, Canada (H.W.).
Anesthesiology. 2020 Jun;132(6):1528-1539. doi: 10.1097/ALN.0000000000003265.
While persistent opioid use after surgery has been the subject of a large number of studies, it is unknown how much variability in the definition of persistent use impacts the reported incidence across studies. The objective was to evaluate the incidence of persistent use estimated with different definitions using a single cohort of postoperative patients, as well as the ability of each definition to identify patients with opioid-related adverse events.
The literature was reviewed to identify observational studies that evaluated persistent opioid use among opioid-naive patients requiring surgery, and any definitions of persistent opioid use were extracted. Next, the authors performed a population-based cohort study of opioid-naive adults undergoing 1 of 18 surgical procedures from 2013 to 2017 in Ontario, Canada. The primary outcome was the incidence of persistent opioid use, defined by each extracted definition of persistent opioid use. The authors also assessed the sensitivity and specificity of each definition to identify patients with an opioid-related adverse event in the year after surgery.
Twenty-nine different definitions of persistent opioid use were identified from 39 studies. Applying the different definitions to a cohort of 162,830 opioid-naive surgical patients, the incidence of persistent opioid use in the year after surgery ranged from 0.01% (n = 10) to 14.7% (n = 23,442), with a median of 0.7% (n = 1,061). Opioid-related overdose or diagnosis associated with opioid use disorder in the year of follow-up occurred in 164 patients (1 per 1,000 operations). The sensitivity of each definition to identify patients with the composite measure of opioid use disorder or opioid-related toxicity ranged from 0.01 to 0.36, while specificity ranged from 0.86 to 1.00.
The incidence of persistent opioid use reported after surgery varies more than 100-fold depending on the definition used. Definitions varied markedly in their sensitivity for identifying adverse opioid-related event, with low sensitivity overall across measures.
尽管手术后持续使用阿片类药物已成为大量研究的主题,但尚不清楚在定义持续性使用方面的差异对研究报告的发生率有多大影响。目的是使用单一的术后患者队列评估使用不同定义估计的持续性使用发生率,以及每种定义识别与阿片类药物相关的不良事件患者的能力。
文献综述旨在确定评估接受手术的阿片类药物初治患者持续性阿片类药物使用的观察性研究,并提取任何持续性阿片类药物使用的定义。接下来,作者对 2013 年至 2017 年期间在加拿大安大略省接受 18 种手术之一的阿片类药物初治成年人进行了一项基于人群的队列研究。主要结局是通过每种提取的持续性阿片类药物使用定义来定义的持续性阿片类药物使用的发生率。作者还评估了每种定义识别术后一年内与阿片类药物相关的不良事件患者的敏感性和特异性。
从 39 项研究中确定了 29 种不同的持续性阿片类药物使用定义。将这些不同的定义应用于 162,830 名阿片类药物初治手术患者的队列中,术后一年内持续性阿片类药物使用的发生率范围为 0.01%(n = 10)至 14.7%(n = 23,442),中位数为 0.7%(n = 1,061)。在随访期间,有 164 名患者(每 1,000 例手术中有 1 例)发生了与阿片类药物使用障碍或与阿片类药物相关的毒性相关的阿片类药物相关药物过量或诊断。每种定义识别出阿片类药物使用障碍或阿片类药物相关毒性综合指标的患者的敏感性范围为 0.01 至 0.36,而特异性范围为 0.86 至 1.00。
手术后报告的持续性阿片类药物使用的发生率因所使用的定义而异,差异超过 100 倍。定义在识别不良阿片类药物相关事件的敏感性方面差异很大,总体敏感性较低。